Jason Park is the founder of Empress Therapeutics. Empress Therapeutics has raised $50M in total funding. Latest round: Series A.
Jason Park is the CEO and co-founder of Empress Therapeutics, a small-molecule drug development company launched in 2023 by Flagship Pioneering. He also serves as an Operating Partner at Flagship Pioneering, where he leads the development of science, intellectual property, and business strategy for new companies. Before joining Flagship, he was with the Boston Consulting Group and held leadership roles at other biotech startups.
Full founder directory · Investor directory · Company funding database · Fundraising library